The formulations of the to-be-marketed film coated tablets are the same as the Phase 3 clinical-tablets, except for coating color changes. The provided dissolution profile comparison data fully support the bridging between Phase 3 and to-be-marketed tablets. Early stage (Phase 1 and 2) formulation bridging was accomplished via human BE studies and similar dissolution profiles.